Our mid-to-long term biosimilars and biobetters pipelines are potentially worth dozens of billions of US dollars.


Biosimilars are highly appreciated and their safety and efficacy are well verified by the market. The lower risks and shorter development cycles are only some examples of their advantages.


The company focuses on development of proprietary innovative new drugs. Our exclusively owned long-acting drug platform can be applied to both biosimilars and biobetters. High recovery rate, world-class quality and excellent bioactivity perfectly describe our biobetter products.